Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the successful enrollment of the sixth patient into the safety lead-in cohort of its ongoing Phase 2 trial evaluating Radspherin® for the treatment of peritoneal carcinomatosis from ovarian cancer.
A live streamed of quarterly presentation in English. A webcast will be available for everyone to view on www.oncoinvent.com. There will be a possibility for Q&A through the MS Teams Webinar. Link to live stream: Oncoinvent ASA: Invitation to Result Presentation Q4 2024
In connection with the release of the results for the full year and fourth quarter 2024, Oncoinvent invites to the following events:
Members of management will be presenting the company and participate in Carnegie Healthcare Seminar, Stockholm
Members of management will be presenting the company and participate in the 45th Annual TD Cowen Health Care Conference, Boston
Members of management will be presenting the company and participate in the B. Riley Securities Precision Oncology & Radiopharma Conference.
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will be presenting the company and participate in the following conferences:
Reference is made to the stock exchange announcement by Oncoinvent ASA (“Oncoinvent” or the “Company”) on 6 February 2025 regarding the final result of the subsequent offering in the Company, where a total of 5,500,000 new shares were subscribed and allocated at a subscription price of NOK 2 per share.
Reference is made to the stock exchange announcement by Oncoinvent ASA
(“Oncoinvent” or the “Company”) on 22 January 2025 regarding the launch of a
subsequent offering of up to 5,500,000 new shares (“Offer Shares”) in the
Company, each with a nominal value of NOK 0.10, at a subscription price of NOK 2
per Offer Share (the “Subsequent Offering”), as well as the stock exchange
announcement from earlier today, regarding today being the last day of the
subscription period in the Subsequent Offering.
Reference is made to the stock exchange announcement by Oncoinvent ASA (“Oncoinvent” or the “Company”) on 22 January 2025 regarding the launch of a subsequent offering of up to 5,500,000 new shares (“Offer Shares”) in the Company, each with a nominal value of NOK 0.10, at a subscription price of NOK 2 per Offer Share (the “Subsequent Offering”).
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.